Neuzil Jiri, Stantic Marina, Zobalova Renata, Chladova Jaromira, Wang Xiufang, Prochazka Lubomir, Dong Lanfeng, Andera Ladislav, Ralph Stephen J
Apoptosis Research Group, School of Medical Science, Griffith University, Southport, Qld, Australia.
Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9. doi: 10.1016/j.bbrc.2007.01.159. Epub 2007 Feb 6.
Recent evidence suggests that a subset of cells within a tumour have 'stem-like' characteristics. These tumour-initiating cells, distinct from non-malignant stem cells, show low proliferative rates, high self-renewing capacity, propensity to differentiate into actively proliferating tumour cells, resistance to chemotherapy or radiation, and they are often characterised by elevated expression of the stem cell surface marker CD133. Understanding the molecular biology of the CD133(+) cancer cells is now essential for developing more effective cancer treatments. These may include drugs targeting organelles, such as mitochondria or lysosomes, using highly efficient and selective inducers of apoptosis. Alternatively, agents or treatment regimens that enhance sensitivity of these therapy-resistant "tumour stem cells" to the current or emerging anti-tumour drugs would be of interest as well.
最近的证据表明，肿瘤内的一部分细胞具有“干细胞样”特征。这些肿瘤起始细胞不同于非恶性干细胞，其增殖速率低、自我更新能力强、倾向于分化为活跃增殖的肿瘤细胞、对化疗或放疗具有抗性，并且它们通常以干细胞表面标志物CD133的表达升高为特征。了解CD133(+)癌细胞的分子生物学现在对于开发更有效的癌症治疗方法至关重要。这些方法可能包括使用高效且选择性的凋亡诱导剂来靶向细胞器（如线粒体或溶酶体）的药物。或者，增强这些抗治疗性“肿瘤干细胞”对现有或新出现的抗肿瘤药物敏感性的药物或治疗方案也会很有意义。
